title: Effect of menthol on ocular drug delivery.
abstract: BACKGROUND
  To assess how safe and effective it is to use menthol as a permeability enhancer in ophthalmic drug delivery systems.
  
  
  METHODS
  In this study, the effect of menthol on permeability of dexamethasone disodium phosphate in the cornea and sclera was investigated in vitro. Application of topical drops and subconjunctival injection of dexamethasone disodium phosphate with or without 0.1% menthol was administered to rabbit eyes, and the drug concentration was detected in aqueous humor, cornea, vitreous, and retinochoroidal tissues. The safety of menthol was assessed on the basis of corneal hydration level, Draize test, electroretinography (ERG), and histological examination.
  
  
  RESULTS
  0.05% and 0.1% menthol significantly enhanced the penetration of dexamethasone in the cornea, but did not change the dexamethasone penetration in sclera in vitro. When topical drops of dexamethasone containing 0.1% menthol were administered, a significantly increased concentration of dexamethasone in the cornea and aqueous humor tissues was reported, but dexamethasone concentrations remained unaffected in the retina-choroid tissues. On the other hand, increased drug concentration in aqueous humor, cornea, vitreous and retinochoroidal tissues was achieved through subconjunctival injection. No signs of irritation were observed when menthol was administered at concentrations ranging from 0.025%-0.1%; moreover, no substantial toxic reactions were observed in corneal hydration level, electrophysiological, or histological examinations after the addition of 0.1% menthol.
  
  
  CONCLUSIONS
  Menthol may improve the ocular penetration of a drug in a transcorneal and transscleral drug delivery system without causing toxic reactions.
authors: Department of Ophthalmology, The First Affiliated Hospital of Harbin Medical University, No.23 Youzheng street, Nangang District, Harbin, 150001, Heilongjiang Province, People's Republic of China.
authors: Xiaolin
authors: X
authors: Xu
authors: Nannan
authors: N
authors: Yu
authors: Zhengzhong
authors: Z
authors: Bai
authors: Yanbin
authors: Y
authors: Xun
authors: Di
authors: D
authors: Jin
authors: Zhijian
authors: Z
authors: Li
authors: Hao
authors: H
authors: Cui
references: Eur J Pharm Biopharm. 2005 Jul;60(2):227-40
references: 15939235
references: J Control Release. 2005 Sep 2;106(3):386-90
references: 16026884
references: Drug Saf. 2002;25(1):33-55
references: 11820911
references: Invest Ophthalmol Vis Sci. 2005 Feb;46(2):703-8
references: 15671302
references: Ophthalmology. 2002 Oct;109(10):1887-91
references: 12359610
references: Int J Pharm. 2002 Jan 31;232(1-2):139-47
references: 11790497
references: J Control Release. 1998 Feb 12;51(2-3):301-11
references: 9685928
references: Skin Pharmacol Physiol. 2006;19(1):17-21
references: 16247245
references: J Pharm Sci. 1997 Dec;86(12):1394-9
references: 9423153
references: Curr Drug Deliv. 2006 Apr;3(2):207-17
references: 16611007
references: Drug Discov Today. 2008 Feb;13(3-4):135-43
references: 18275911
references: J Pharm Sci. 1997 Dec;86(12):1369-73
references: 9423148
references: J Ocul Pharmacol Ther. 2005 Feb;21(1):1-10
references: 15718823
references: Graefes Arch Clin Exp Ophthalmol. 1993 Mar;231(3):157-61
references: 8462888
references: J Am Acad Dermatol. 2007 Nov;57(5):873-8
references: 17498839
references: Drug Deliv. 2009 May;16(4):224-9
references: 19514982
references: Pharm Dev Technol. 2002;7(3):305-15
references: 12229262
references: Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2543-8
references: 15277475
references: Chem Pharm Bull (Tokyo). 1996 Feb;44(2):403-8
references: 8998843
references: J Ocul Pharmacol Ther. 2002 Dec;18(6):559-69
references: 12537682